Imaging of prostate cancer with positron emission tomography

Michael E. Zimmerman, Alexa R. Meyer, Steven P. Rowe, Michael A. Gorin

Research output: Contribution to journalArticle

Abstract

Prostate cancer is most commonly imaged through a combination of magnetic resonance imaging, x-ray computed tomography, and99mTc-methylene diphosphonate bone scan. Hese conventional imaging modalities, however, suffer from limited sensitivity and specificity for the detection of disease. This can lead to disease understaging and the improper selection of treatment. To address this problem, a variety of novel radiotracers for positron emission tomography (PET) imaging have been developed. This includes agents that accumulate on the basis of alterations in cellular metabolism (eg,11C-choline and 18F-FACBC) as well as those that bind to specific proteins (eg,68Ga-PSMA-11,18F-DCFPyL, 68Ga- RM2, and18F-DHT). In this review, we examine the performance characteristics of these new PET radiotracers for imaging prostate cancer and discuss ways in which PET imaging can offer more precise clinical information to patients and providers.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume17
Issue number8
StatePublished - Aug 1 2019

Keywords

  • Cancer diagnostics
  • PET
  • Positron emission tomography
  • Prostate cancer imaging
  • Radiotracers

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Imaging of prostate cancer with positron emission tomography'. Together they form a unique fingerprint.

  • Cite this